FibroBiologics, Inc. (FBLG): R&D Expense
$7.41M
Year ended 2025-12-31
$8.20M
Trailing 12 months to 2026-06-30
+86.2%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.41M | +64.5% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $4.50M | +90.2% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $2.37M | +106.5% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $1.15M | n/a | 2024-02-29, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $7.41M | +64.5% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $453.7K | -95.5% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $5.05M | -59.7% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $18.78M | -15.0% |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $9.34M | +28.8% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $7.49M | +43.3% |
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $7.72M | +118.9% |
Compare FBLG, MAIA, COCP, CANF side by side · Screen every company in Pharmaceutical Preparations ↗